. Author manuscript; available in PMC: 2017 Jan 1.

Published in final edited form as: J Neurooncol. 2016 Jan;126(1):193–200. doi: 10.1007/s11060-015-1959-y

Table 2. Progression free survival rates by clinical parameters.

		n	Actuarial 2-year PFS (95 % CI)	Estimated 5-year PFS (95 % CI)	Hazard ratio (95 % CI)	p value (log-rank)
Entire cohort		28	75 % (53–88 %)	54 % (31–72 %)
MIB labeling index	MIB-1 ≤ 4 %	13	90 % (47–99 %)	90 % (47–99 %)	0.18 (0.04–0.44)	0.0026
MIB labeling index	MIB-1> 4 %	11	48 % (16–74 %)	12 % (1–41 %)
Percent resection	>80 %	14	83 % (46–95 %)	48 % (16–75 %)	0.67 (0.23–2.0)	0.47
Percent resection	≤80 %	14	67 % (34–86 %)	57 % (25–80 %)
Tumor size	≤4.1	14	75 % (41–91 %)	54 % (21–78 %)	0.87 (0.27–2.7)	0.80
Tumor size	>4.1	13	82 % (45–95 %)	60 % (24–83 %)
Overall resection extent	GTR	9	75 % (31–93 %)	40 % (7–73 %)	1.4 (0.41–5.2)	0.57
Overall resection extent	STR	19	76 % (47–90 %)	61 % (32–80 %)
Resection extent ± adjuvant radiotherapy	STR + RT	3	100 % (NA)	67 % (6–95 %)	NA	0.049
Resection extent ± adjuvant radiotherapy	STR – RT	16	70 % (38–88 %)	53 % (23–76 %)